Adamis Pharmaceuticals Corp (ADMP)

[H2R]

Positive SA Article

https://seekingalpha.com/article/4209722-adamis-novartis-gunning-mylans-epipen

Adamis finds itself today with the wind at its back. With the lucrative 50/50 profit split with Sandoz, the qualitative superiority of Symjepi in its size and ease of use, the FDA's recent approval of Symjepi Jr., a cash supply big enough to last until 2020, and the shortage of epinephrine auto-injectors, the environment is ripe for Adamis and its shareholders.

Additionally, new investors have a considerable margin of safety in that share price remains depressed for reasons that were once justifiable, but are now outright arbitrary. Despite the changing landscape, lingering animosities and contempt towards management has irrationally kept the share price depressed, leaving very little room for price to fall-unlike the cases with more pricey biotechs like GERN and OMER who took massive haircuts recently. Although management has had a rocky history with its investors, it nonetheless has secured major successes in the Sandoz commercial deal and the FDA approval of Symjepi Jr.